QLT in a Rut or Ready for a Comeback?

Last week, drug developer QLT (Nasdaq: QLTI  ) released its third-quarter results and guidance for the rest of the year.

Depending on how you envision the future unfolding for QLT's age-related macular degeneration (AMD) drug Visudyne, you can take this quarter's 25% drop in revenue and 35% Visudyne sales shortfall as either a signal of more bad times to come or a bump in the road until the future improves.

There's nothing new this quarter to the story about the sales shortfall with Visudyne. As Genentech's (NYSE: DNA  ) rival AMD treatment Lucentis gets rolled out in more European countries, sales of Visudyne head into a free fall in each market that experiences the new competition.

Both Visudyne and Lucentis are marketed by Novartis (NYSE: NVS  ) in the European Union. In order to expand the market for Visudyne, Novartis and QLT have been running several combination studies with the two AMD drugs to see if there are clinically meaningful efficacy improvements with using them together.

Interim six-month results from one of these studies are expected to be out before the end of 2008, with more trial results coming in 2009. QLT's hope is that if these studies are successful, it will be able to keep Visudyne worldwide sales in a range of $200 million to $250 million a year even with the continual penetration of Lucentis into new markets.   

The rest of the QLT story remains the same; acne treatment Aczone has a March 23 FDA PDUFA target date for the possible label improvements that QLT is seeking before it markets or out-licenses the drug. If the FDA approves the less-burdensome label, then QLT is guiding for $100 million in peak annualized sales from the drug.


The 2007 sales guidance range for hormone therapy drug Eligard was upped thanks to continued penetration of the six-month formulation in Europe. Sales are now expected to be in the $175 million to $185 million range, compared to an earlier 2007 range of $160 million to $180 million, which itself was the product of raised guidance.

With the continued decline of income from Visudyne, QLT experience a small $2.6 million operating loss for the quarter. Whether this is a sign of continued fiscal deterioration or the bottoming out of its fortunes likely depends on the results of those Visudyne combination studies. Place your bets accordingly.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 539317, ~/Articles/ArticleHandler.aspx, 9/2/2014 8:30:22 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement